CoChat

Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study

Open access
Domingues, Carla Magda Allan S, Verani, Jennifer R, Montenegro Renoiner, Ernesto Issac, de Cunto Brandileone, Maria Cristina, Flannery, Brendan, de Oliveira, Lucia Helena, Santos, João Barberino, de Moraes, José Cássio · 2014 · The Lancet Respiratory Medicine
Cited by 221

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Summary Background In March 2010, Brazil introduced the ten-valent pneumococcal conjugate vaccine (PCV10), which was licensed based on non-inferiority of immunological correlates of protection compared with the seven-valent vaccine. The schedule comprised three primary doses at ages 2 months, 4 months, and 6 months, and a booster dose at age 12 months. A single catch-up dose was offered for children aged 12–23 months at the time of introduction. We assessed PCV10 effectiveness against invasive pneumococcal disease in Brazilian children. Methods Invasive pneumococcal disease, defined as isolation of Streptococcus pneumoniae from blood, cerebrospinal fluid, or another normally sterile site, was identified in children age-eligible for at least one PCV10 dose through laboratory-based and hospital-based surveillance in ten states in Brazil from March 1, 2010, until Dec 31, 2012. We aimed to identify four age-matched and neighbourhood-matched controls for each case. We used conditional logistic regression and calculated PCV10 effectiveness as (1–adjusted matched odds ratio) × 100% for vaccine-type and vaccine-related serotypes (ie, in the same serogroup as a vaccine serotype). Findings In 316 cases (median age 13·2 months, range 2·6–53·1) and 1219 controls (13·3 months, 2·6–53·1), the adjusted effectiveness of an age-appropriate PCV10 schedule was 83·8% (95% CI 65·9–92·3) against vaccine serotypes, and 77·9% (41·0–91·7) against vaccine-related serotypes. Serotype-specific effectiveness was shown for the two most common vaccine serotypes—14 (87·7%, 60·8–96·1) and 6B (82·8%, 23·8–96·1)—and serotype 19A (82·2%, 10·7–96·4), a serotype related to vaccine serotype 19F. A single catch-up dose in children aged 12–23 months was effective against vaccine-type disease (68·0%, 17·6–87·6). No significant effectiveness was shown against non-vaccine serotypes for age-appropriate or catch-up schedules. Interpretation In the routine immunisation programme in Brazil, PCV10 prevents invasive disease caused by vaccine serotypes. PCV10 might provide cross-protection against some vaccine-related serotypes. Funding Brazilian Ministry of Health, Pan-American Health Organization, and US Centers for Disease Control and Prevention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(14)70060-8

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 221

Metadata

Authors
Domingues, C. M. A. S., Verani, J. R., Montenegro Renoiner, E. I., de Cunto Brandileone, M. C., Flannery, B., de Oliveira, L. H., Santos, J. B., & de Moraes, J. C.
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2014-06
Volume
2
Issue
6
Pages
464-471
ISSN
2213-2600 (ISSN-L)
OpenAlex
W2127699766
Cited by
221
References
3
FWCI
22.70
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. https://app.cochat.ai/papers/10.1016/s2213-2600(14)70060-8
The paper
Domingues, C. M. A. S., Verani, J. R., Montenegro Renoiner, E. I., de Cunto Brandileone, M. C., Flannery, B., de Oliveira, L. H., Santos, J. B., & de Moraes, J. C. (2014). Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(14)70060-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.